Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $63.28 (market cap $78.49B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 16.1× Travere Therapeutics Inc. Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.38% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 108 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MDLZ | TVTX | |
|---|---|---|
Market Cap | $78.49B | $4.88B |
Volume | 7,021,971 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $67.52 |
52-Week Low | $51.51 | $26.79 |
Typical Hold Time | 108 Days | 0 Days |
Enterprise Value | $98.84B | $5.01B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $62.57, up 1.26% with strong technical momentum and bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth continues with $38.54B in 2025, though net margins compressed to 6.36% from previous highs. Analyst consensus remains strongly bullish with a $70.29 price target, supported by recent dividend increases and strategic expansions.
MDLZ offers stable growth with defensive characteristics amid market volatility. Key opportunities include margin recovery from productivity gains and emerging market expansion. Risks include persistent cocoa cost pressures and competitive snack category dynamics. The stock presents a compelling risk-reward profile for long-term investors seeking quality consumer staples exposure.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
